SCHEMBL4323748

SCHEMBL4323748

Cc1cccc(C2C(C#N)=C(N)Oc3cc(N(C)C)ccc32)c1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 9/20 0.78
KMT2A Q03164 9/20 0.78
MAPT P10636 7/20 0.78
NPSR1 Q6W5P4 5/20 0.78
HTT P42858 4/20 0.78
TSHR P16473 4/20 0.78
LMNA P02545 4/20 0.78
GAA P10253 3/20 0.78
MAPK1 P28482 3/20 0.78
ALOX15 P16050 3/20 0.78
CASP1 P29466 3/20 0.78
TP53 P04637 2/20 0.78
USP2 O75604 2/20 0.78
CASP7 P55210 2/20 0.78
TUBB4A P04350 2/20 0.59
TUBB P07437 2/20 0.59
TUBA3C P0DPH7 2/20 0.59
TUBA1B P68363 2/20 0.59
TUBA4A P68366 2/20 0.59
TUBB4B P68371 2/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30628032 1.00 MEN1 (0.78) MEN1KMT2AMAPTNPSR1HTT
SCHEMBL4331766 0.92 MEN1 (0.83) MEN1KMT2AMAPTNPSR1HTT
SCHEMBL4323896 0.91 MEN1 (0.70) MEN1KMT2AMAPTNPSR1HTT
SCHEMBL4331607 0.89 MEN1 (0.79) MEN1KMT2AMAPTNPSR1HTT
SCHEMBL4333678 0.88 MEN1 (0.78) MEN1KMT2AMAPTNPSR1HTT
SCHEMBL30628022 0.88 POLB (0.73) MEN1KMT2AMAPTNPSR1HTT
SCHEMBL28644827 0.88 POLB (0.73) MEN1KMT2AMAPTNPSR1HTT
SCHEMBL30628026 0.87 KMT2A (1.00) MEN1KMT2AMAPTNPSR1HTT
SCHEMBL4337184 0.87 MEN1 (0.76) MEN1KMT2AMAPTNPSR1HTT
SCHEMBL4330036 0.87 KMT2A (1.00) MEN1KMT2AMAPTNPSR1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7507762-B2 Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. (US) 2009-03-24 US claimed
US-20050154015-A1 Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. (US) 2005-07-14 US claimed
EP-1230232-B1 SUBSTITUTED 4H-CHROMENE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF CYTOVIA INC (US) 2004-02-25 EP claimed
EP-1230232-A2 SUBSTITUTED 4H-CHROMENE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF Cytovia, Inc. (US) 2002-08-14 EP claimed
WO-2001034591-A2 SUBSTITUTED 4H-CHROMENE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF CYTOVIA, INC. (US) 2001-05-17 WO claimed
CN-113620919-B Mechanical ball milling assisted synthesis method of 2-amino-3-cyano-4H-pyran compound 浙江工业大学 2023-12-12 CN disclosed
CN-113620919-A Mechanical ball-milling auxiliary synthesis method of 2-amino-3-cyano-4H-pyran compounds 浙江工业大学 2021-11-09 CN disclosed
US-7507762-B2 Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. (US) 2009-03-24 US disclosed
US-20050154015-A1 Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. (US) 2005-07-14 US disclosed
US-6906203-B1 Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. (US) 2005-06-14 US disclosed
EP-1230232-B1 SUBSTITUTED 4H-CHROMENE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF CYTOVIA INC (US) 2004-02-25 EP disclosed
EP-1230232-A2 SUBSTITUTED 4H-CHROMENE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF Cytovia, Inc. (US) 2002-08-14 EP disclosed
WO-2001034591-A2 SUBSTITUTED 4H-CHROMENE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF CYTOVIA, INC. (US) 2001-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050154015-A1 Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof CASP4, CASP3, CASP5 MEN1 2868/4885KMT2A 3138/4885MAPT 4779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.